Common blood pressure drug helps more stroke survivors reach critical health target

The REDUCE trial found spironolactone lowered blood pressure by nearly eight points in stroke survivors, but key questions about prevention remain.
Common blood pressure drug helps more stroke survivors reach critical health target

The REDUCE trial investigated whether adding spironolactone to post-stroke treatment could lower elevated blood pressure. Results showed a significant reduction in blood pressure among participants taking spironolactone compared to those receiving usual care, with more patients reaching their target blood pressure goal. While encouraging, the study did not definitively prove that the medication prevents subsequent strokes, and larger trials are required.

  • A new study, the REDUCE trial, explored adding spironolactone to post-stroke care to lower blood pressure.
  • Participants taking spironolactone experienced an average blood pressure drop of nearly eight points after three months compared to usual care.
  • More patients on spironolactone reached the recommended blood pressure goal (less than 130/80) than those on usual care (52% vs. 30%).
  • Spironolactone helps the body eliminate excess salt and water, lowering blood pressure.
  • Potential side effects include high potassium levels and dizziness.
  • The study ended early and was not designed to prove stroke or heart attack prevention.
  • Larger and longer studies are needed to determine if spironolactone prevents future strokes or heart attacks.
Write a comment